research Preliminary Investigation on Microneedling with Low-Level LED Therapy and Growth Factors in Hair Loss Related to COVID-19
The treatment might help COVID-19 related hair loss, but more research is needed.
Search
forLearn
0 / 0 results — no results
Research
5 / 6 results research Hair Growth Booster Effects of Micro-Needling With Low-Level LED Therapy and Growth Factors on Subjects Treated With Finasteride
Combining micro-needling, LED therapy, and growth factors with Finasteride® significantly improves hair growth.
research Regenerative Biotechnologies in Plastic Surgery: A Multicentric, Retrospective, Case-Series Study on the Use of Microneedling with Low-Level Light/Laser Therapy as a Hair Growth Boost in Patients Affected by Androgenetic Alopecia
Micro-needling with low-level light therapy effectively increases hair growth in people with mild to moderate hair loss.
research Medicinal and Cosmetic Products Used in Treatment of Hair Loss
Some treatments for hair loss, like finasteride, biotin, and minoxidil, can be effective, but their success varies by individual case.
research Potential Factors Contributing to Androgenetic Alopecia
Male pattern baldness may be caused by factors like poor blood circulation, scalp tension, stress, and hormonal imbalances, but the exact causes are still unclear.
Community Join
2 / 2 resultscommunity Our Follicles, who art in hairven, hallowed be thy name; thy hairdom come; thy will be done; on earth as it is in hairven. Give us this day our daily regrowth. And forgive us our hat usage, as we forgive those who own hair against us. And lead us not into transplantation; but deliver us from balding
A 21-year-old with accelerated hair loss due to stress and weight loss is using minoxidil, finasteride, and microneedling to combat balding, despite experiencing a significant initial hair shed. They are committed to continuing treatment for at least three months and are considering switching to topical finasteride if necessary.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.